Reversible hepatotoxicity of paroxetine in a patient with major depression

Pharmacopsychiatry

Volumn 29, Issue 6, 1996, Pages 223-226

  Helmchen, C ^a   Boerner, R J ^a   Meyendorf, R ^a   Hegerl, U ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DRUG MECHANISM; FEMALE; HUMAN; LIVER TOXICITY; NAUSEA; PRIORITY JOURNAL;

EID: 0029809175     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979576     Document Type: Article

References (24)

1. Beaumont, G., S. Kasper, J. O. Hanlon, J. Mendlewicz: Antidepressant side effects and adverse reactions. Depression 2 (1995) 138-144
2. Bendele, R. A., E. R. Adams, W. P. Hoffman et al.: Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res. 52 (1992) 6931-6935
3. Berson, A., E. Freneaux, D. Larrey et al.: Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J. Hepatology 20 (1994) 336-342
4. Bobichon, R., G. Bernard, F. Mion: Atteinte hepatique aigue lors d'un traitement par la fluoxetine. Gastroenterol. Clin. Biol. 17 (1993) 406-407
5. Bodner, R. A., T. Lynch, L. Lewis, D. Kahn: Serotonin syndrome. Neurology 45 (1995) 219-223
6. Boyer, W. F., C. L. Blumenhardt: The safety of paroxetine. J. Clin. Psychiatry 53 (1992) 61-63
7. Brosen, K.: The pharmacogenectics of the selective serotonin reuptake inhibitors. Clinical Investigator 71 (1993) 1002-1009
8. Castiella, A., J. I. Arenas: Fluoxetine hepatotoxicity. Amer. J. Gastroenterol. 89 (1994) 458-459
9. Criteria of drug-induced liver disorders. Report of an international Consensus Meeting. J. Hepatology 11 (1990) 272-276
10. Dalhoff, K., T. P. Almdal, K. Bjerrum, S. Keiding, H. Mengel, J. Lund: Pharmacokinetics of paroxetine in patients with cirrhosis. Eur. J. Clin. Pharmacol. 41 (1991) 351-354
11. Davis, M.: Hepatotoxicity of antidepressants. Internat. Clin. Psychopharmacol. 6 (1991) 97-103
12. DeVane, C. L.: Pharmacokinetics of the newer antidepressants: clinical relevance. Amer. J. Medicine 97, Suppl. 6A (1994) 6A-13S
13. Dunbar, G. C.: A comparison of paroxetine, imipramine and placebo in depressed outpatients. Brit. J. Psychiatry 159 (1991) 394-398
14. Goodnick, P. J.: Pharmacokinetic optimisation of therapy with newer antidepressants. Clin. Pharmacokinet. 27 (1994) 307-330
15. Green, B. H.: Fluvoxamine and hepatic function. Brit. J. Psychiatry 153 (1988) 130-131
16. Hawley, C. J., A. G. Roberts, M. H. Walker: Tolerability of combined treatment with lithium and paroxetine: 19 cases treated under open conditions. J. Psychopharmacol. 8 (1994) 266-267
17. Kasper, S., J. P. Lepine, J. Mendlewicz, S. A. Montgomery, A. J. Rush: Efficacy, safety, and indications for tricyclic and newer antidepressants. Depression 2 (1995) 127-137
18. Kaye, C. M., R. E. Haddock, P. F. Langley et al.: A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr. Scand. 80, Suppl. 350 (1989) 60-75
19. Kosson, H., J. C. Chou: Abnormal liver function tests associated with lithium treatment. J. Clin. Psychopharmacol. 12 (1992) 217-218
20. Kuhs, H., H. P. Schlake, L. H. Rolf, G. E. Rudolf: Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline. Acta Psychiatr. Scand. 85 (1992) 364-369
21. Lam, K. S., A. Blanchi, J. M. Chavaillon: Hepatite probablement secondaire a la prise massive de fluvoxamine. Gastroenterol. Clin. Biol. 12 (1988) 398-399
22. Larray, D., B. Rueff, D. Pessayre et al.: Cross-hepatotoxicity between tricyclic antidepressants. Gut 27 (1986) 726-727
23. Mars, F., G. Dumas, P. Gorssen: Hepatite aigue lors du traitement par la fluoxetine. Gastroenterol. Clin. Biol. 15 (1991) 270-271
24. Menon, R. R., R. Howard: Sertraline and liver toxicity in the elderly. Int. J. Geriatr. Psychiatry 9 (1994) 332-334